Literature DB >> 11028470

Short- and long-term mortality for patients undergoing primary angioplasty for acute myocardial infarction.

E L Hannan1, M J Racz, D T Arani, T J Ryan, G Walford, B D McCallister.   

Abstract

OBJECTIVES: The goal of this study was to learn more about the risk factors and short- and long-term outcomes for primary angioplasty.
BACKGROUND: Primary angioplasty (direct angioplasty without antecedent thrombolytic therapy) has been an effective alternative to thrombolytic therapy for patients with acute myocardial infarction (AMI). However, most reported studies have been compromised by small sample sizes and short observation times.
METHODS: New York's coronary angioplasty registry was used to identify New York patients undergoing angioplasty within 6 h of AMI between January 1, 1993 and December 31, 1996. Statistical models were used to identify significant risk factors for in-patient and long-term survival and to estimate long-term survival for all patients as well as various subsets of patients undergoing primary angioplasty.
RESULTS: The in-hospital mortality rate for all primary angioplasty patients was 5.81%. When patients in preprocedural shock (who had a mortality rate of 45%) were excluded, the in-hospital mortality rate dropped to 2.60%. Mortality rates for all primary angioplasty patients at one year, two years and three years were 9.3%, 11.3% and 12.6%, respectively. Patients treated with stent placement did not have significantly lower risk-adjusted in-patient or two-year mortality rates.
CONCLUSIONS: Primary angioplasty is a highly effective option for AMI.

Entities:  

Mesh:

Year:  2000        PMID: 11028470     DOI: 10.1016/s0735-1097(00)00866-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

Review 1.  Acute coronary syndromes in patients with renal failure.

Authors:  Peter A McCullough
Journal:  Curr Cardiol Rep       Date:  2003-07       Impact factor: 2.931

2.  Five year outcome after primary coronary intervention for acute ST elevation myocardial infarction: results from a single centre experience.

Authors:  G Parodi; G Memisha; R Valenti; M Trapani; A Migliorini; G M Santoro; D Antoniucci
Journal:  Heart       Date:  2005-04-06       Impact factor: 5.994

3.  Long-term impact of multivessel disease on cause-specific mortality after ST elevation myocardial infarction treated with reperfusion therapy.

Authors:  R J van der Schaaf; J R Timmer; J P Ottervanger; J C A Hoorntje; M-J de Boer; H Suryapranata; F Zijlstra; J-H E Dambrink
Journal:  Heart       Date:  2006-04-27       Impact factor: 5.994

Review 4.  Cardiorenal disease: a clinical intersection.

Authors:  Vikram Kalra; Sandeep Mahajan; Sanjay Kumar Agarwal; Suresh Chander Tiwari
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

5.  Pre-hospital fibrinolysis followed by angioplasty or primary angioplasty in acute myocardial infarction: the long-term clinical outcome.

Authors:  J Roncalli; F Brunelle; M Galinier; D Carrié; J Fourcade; M Elbaz; J P Gaston; S Charpentier; J Puel; J M Fauvel
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

Review 6.  Timing of bypass surgery in stable patients after acute myocardial infarction.

Authors:  Ramya Raghavan; Bruno S Benzaquen; Lawrence Rudski
Journal:  Can J Cardiol       Date:  2007-10       Impact factor: 5.223

7.  Gender differences in management and outcomes in patients with acute coronary syndromes: results on 20,290 patients from the AMIS Plus Registry.

Authors:  Dragana Radovanovic; Paul Erne; Philip Urban; Osmund Bertel; Hans Rickli; Jean-Michel Gaspoz
Journal:  Heart       Date:  2007-11       Impact factor: 5.994

8.  Hospital mortality in acute coronary syndrome: differences related to gender and use of percutaneous coronary procedures.

Authors:  María J Aguado-Romeo; Soledad Márquez-Calderón; María L Buzón-Barrera
Journal:  BMC Health Serv Res       Date:  2007-07-13       Impact factor: 2.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.